<DOC>
	<DOCNO>NCT01717950</DOCNO>
	<brief_summary>Hookworms digest hemoglobin erythrocyte use energy source via proteolytic cascade begin aspartic protease , APR-1 . Vaccination recombinant APR-1 protect animal infection challenge study . This study evaluate safety immunogenicity two formulation Na-APR-1 ( M74 ) healthy adult volunteer co-administered different concentration immunostimulant GLA-AF .</brief_summary>
	<brief_title>Safety Immunogenicity Na-APR-1 Hookworm Vaccine Healthy Adults</brief_title>
	<detailed_description>Open-label , dose-escalation phase 1 clinical trial healthy , hookworm-naïve adult : - Study site : George Washington Medical Faculty Associates , Washington , DC - Number participant : 40 2 cohort 20 . In Cohort 1 five ( 5 ) volunteer receive 30 µg Na-APR-1 ( M74 ) /Alhydrogel® , five ( 5 ) receive 30 µg Na-APR-1 ( M74 ) /Alhydrogel® plus 2.5 µg GLA-AF , ten ( 10 ) receive 30 µg Na-APR-1 ( M74 ) /Alhydrogel® plus 5 µg GLA-AF . In Cohort 2 five ( 5 ) volunteer receive 100 µg Na-APR-1 ( M74 ) /Alhydrogel® , five ( 5 ) receive 100 µg Na-APR-1 ( M74 ) /Alhydrogel® plus 2.5 µg GLA-AF , ten ( 10 ) receive 100 µg Na-APR-1 ( M74 ) /Alhydrogel® plus 5 µg GLA-AF . The cohort enrol staggered fashion safety data assess prior Na-APR-1 dose escalation 30 100 µg . In addition , within cohort , vaccination stagger formulation contain 0 , 2.5 , 5 µg GLA-AF test sequentially : example , receive Na-APR-1 ( M74 ) /Alhydrogel® combination 2.5 µg GLA-AF vaccinate sooner 3 day last volunteer vaccinate formulation contain GLA-AF , whereas vaccinate Na-APR-1 ( M74 ) /Alhydrogel® plus 5 µg GLA-AF vaccinate sooner 7 day last one receive 2.5 µg GLA-AF formulation . - Immunization schedule : Study day 0 , 56 112 . - Route : IM deltoid muscle . - Doses Na-APR-1 ( M74 ) test : 30 100 µg . - Doses Alhydrogel® : 240 800 µg 30 100 µg dos Na-APR-1 ( M74 ) , respectively . - Doses GLA-AF test : 2.5 µg 5 µg . - Study duration : 44 week ( 10 month ) per study participant ; total duration study estimate approximately 13 month .</detailed_description>
	<mesh_term>Hookworm Infections</mesh_term>
	<mesh_term>Ancylostomiasis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>Males females 18 50 year , inclusive . Good general health determine mean screening procedure . Available duration trial ( 44 week ) . Willingness participate study evidence sign informed consent document . Pregnancy determine positive urine human choriogonadotropin ( hCG ) ( female ) . Participant unwilling use reliable contraception method one month follow third immunization ( female surgically sterile , abstinent least 2 year postmenopausal ) . Currently lactate breastfeed ( female ) . Evidence clinically significant neurologic , cardiac , pulmonary , hepatic , rheumatologic , autoimmune , diabetes , renal disease history , physical examination , and/or laboratory study . Known suspected immunodeficiency . Laboratory evidence liver disease ( alanine aminotransferase [ ALT ] great 1.25times upper reference limit ) . Laboratory evidence renal disease ( serum creatinine great 1.25times upper reference limit , trace protein blood urine dipstick test ) . Laboratory evidence hematologic disease ( hemoglobin &lt; 11.5 g/dl [ female ] &lt; 12.5 g/dl [ male ] ; absolute leukocyte count &lt; 3600/mm3 &gt; 10.7 x 103/mm3 ; absolute neutrophil count [ ANC ] &lt; 1700/ mm3 ; absolute lymphocyte count &lt; 700/mm3 ; platelet count &lt; 140,000/mm3 ) . Laboratory evidence coagulopathy ( PTT PT INR great 1.1times upper reference limit ) . Serum glucose ( random ) great 1.2times upper reference limit . Other condition opinion investigator would jeopardize safety right volunteer participate trial would render subject unable comply protocol . Participation another investigational vaccine drug trial within 30 day start study . Volunteer medical , occupational , family problem result alcohol illicit drug use past 12 month . History severe allergic reaction anaphylaxis . Severe asthma define need daily use inhaler emergency clinic visit hospitalization within 6 month volunteer 's expect first vaccination study . Positive ELISA hepatitis B surface antigen ( HBsAg ) . Positive confirmatory test HIV infection . Positive confirmatory test hepatitis C virus ( HCV ) infection . Use corticosteroid ( exclude topical nasal ) immunosuppressive drug within 30 day volunteer 's expect first vaccination study . Receipt live vaccine within 4 week kill vaccine within 2 week prior volunteer 's expect first vaccination study . History surgical splenectomy . Receipt blood product within past 6 month . History previous infection hookworm residence 6 month hookwormendemic area .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Human Hookworm</keyword>
	<keyword>Necator americanus</keyword>
	<keyword>Hookworm</keyword>
	<keyword>Hookworm Disease</keyword>
	<keyword>Iron-deficiency anemia</keyword>
	<keyword>Soil-transmitted helminth infection</keyword>
	<keyword>Neglected Tropical Disease</keyword>
	<keyword>Na-APR-1</keyword>
</DOC>